A recent discovery has established that circ-EGFR deprivation not only suppresses tumorigenicity in brain tumor-initiating cells but also enhances the efficiency of nimotuzumab in the treatment of GBM (Liu et al, 2021), suggesting a compelling link between circ-EGFR and treatment efficacy in cancers. The gene discussed is EGFR; the disease is brain neoplasm.